Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells

Michele Navarra1, Marilena Celano, Jessica Maiuolo

  • 1Pharmaco-Biological Department, University of Messina, viale Annunziata, 98100 Messina, Italy. mnavarra@unime.it

BMC Cancer
|November 6, 2010
PubMed
Abstract

Insights

This study shows a novel pyrazolo-pyrimidine derivative, SI 34, effectively inhibits neuroblastoma cell growth and invasiveness. SI 34 demonstrates potential as a new therapeutic agent for neuroblastoma treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Neuroblastoma (NB) is a common childhood cancer with poor prognosis upon metastasis.
  • Src-family tyrosine kinases (SFKs) are implicated in NB development and invasiveness.

Purpose of the Study:

  • To investigate the anti-cancer effects of novel pyrazolo-pyrimidine derivatives on human neuroblastoma cells.
  • To elucidate the mechanisms underlying the antiproliferative and anti-invasive actions of SI 34.

Main Methods:

  • Cell proliferation was assessed using MTT assays and cell counting.
  • Cell cycle, apoptosis, adhesion, and invasiveness were analyzed.
  • Western blot assays were used to examine the expression of cyclins, Src, and ERK.

Main Results:

  • SI 34, SI 35, and SI 83 inhibited NB cell proliferation in a dose- and time-dependent manner.
  • SI 34 induced apoptosis and G0/G1 cell cycle arrest, decreasing cyclin D1 expression.
  • SI 34 reduced cell adhesion and invasiveness, inhibiting Src and ERK phosphorylation.

Conclusions:

  • The pyrazolo-pyrimidine derivative SI 34 exhibits significant anti-proliferative and anti-invasive activity against human neuroblastoma cells.
  • SI 34's mechanism involves the inhibition of Src and ERK signaling pathways.
  • SI 34 shows promise as a novel therapeutic candidate for neuroblastoma treatment.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...